Related references
Note: Only part of the references are listed.Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy
Kevin A. Hay et al.
BLOOD (2019)
Decitabine plus CLAG chemotherapy as a bridge to haploidentical transplantation in the setting of acute myeloid leukemia relapse after HLA-matched sibling transplantation: a case report
Mengqi Jin et al.
BMC CANCER (2019)
Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia
Juanjuan Zhao et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia
Jing Pan et al.
LEUKEMIA (2019)
Leukemia relapse following unmanipulated haploidentical transplantation: a risk factor analysis on behalf of the ALWP of the EBMT
Simona Piemontese et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients
Yu Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT
Jiri Pavlu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Haploidentical versus unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: a report on 1578 patients from the Acute Leukemia Working Party of the EBMT
Eolia Brissot et al.
HAEMATOLOGICA (2019)
Minimal residual disease status determined by multiparametric flow cytometry pretransplantation predicts the outcome of patients with ALL receiving unmanipulated haploidentical allografts
Xiao-Su Zhao et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Chimeric antigen receptor-modified T cells: CD19 and the road beyond
Alexander I. Salter et al.
BLOOD (2018)
Pre- and post-transplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukaemia
Federica Lovisa et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells
Jae H. Park et al.
CLINICAL INFECTIOUS DISEASES (2018)
Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Dalila Salvatore et al.
HAEMATOLOGICA (2018)
Single-Dose Daily Fractionation Is Not Inferior to Twice-a-Day Fractionated Total-Body Irradiation Before Allogeneic Stem Cell Transplantation for Acute Leukemia: A Useful Practice Simplification Resulting From the SARASIN Study
Yazid Belkacemi et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2018)
CD19 CAR-T cell therapy for relapsed / refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies
Li-Na Zhang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China-recommendations from the Chinese Society of Hematology
Lanping Xu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Jae H. Park et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Cytomegalovirus infections in lung and hematopoietic cell transplant recipients in the Organ Transplant Infection Prevention and Detection Study: A multi-year, multicenter prospective cohort study
Robin K. Avery et al.
TRANSPLANT INFECTIOUS DISEASE (2018)
Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Dalila Salvatore et al.
HAEMATOLOGICA (2018)
Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine
Federica Giannotti et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Potent Anti-leukemia Activities of Chimeric Antigen Receptor-Modified T Cells against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia
Yongxian Hu et al.
CLINICAL CANCER RESEARCH (2017)
Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation
Michael Slade et al.
TRANSPLANT INFECTIOUS DISEASE (2017)
Somatic mutational landscape of AML with inv(16) or t(8;21) identifies patterns of clonal evolution in relapse leukemia
R. Sood et al.
LEUKEMIA (2016)
Impact of age on outcomes of allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in elderly patients with acute myeloid leukemia
Jun Aoki et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Allogeneic Hematopoietic Stem Cell Transplantation in Thirty-Four Pediatric Cases of Mucopolysaccharidosis-A Ten Year Report from the China Children Transplant Group
Jianmin Wang et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy
Yongxian Hu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Matched and mismatched unrelated donor compared to autologous stem cell transplantation for acute myeloid leukemia in first complete remission: a retrospective, propensity score-weighted analysis from the ALWP of the EBMT
Francesco Saraceni et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Minimal Residual Disease at First Achievement of Complete Remission Predicts Outcome in Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
Mingming Zhang et al.
PLOS ONE (2016)
Single-cell genotyping demonstrates complex clonal diversity in acute myeloid leukemia
Amy L. Paguirigan et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Hematopoietic Stem Cell Transplantation Following Unsuccessful Salvage Treatment for Relapsed Acute Lymphoblastic Leukemia in Children
Jiro Inagaki et al.
PEDIATRIC BLOOD & CANCER (2015)
T-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with matched sibling HSCT and unrelated HSCT
Yi Luo et al.
BLOOD (2014)
Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia
Kheira Beldjord et al.
BLOOD (2014)
Treatment of High-Risk Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in Adolescents and Adults According to Early Cytologic Response and Minimal Residual Disease After Consolidation Assessed by Flow Cytometry: Final Results of the PETHEMA ALL-AR-03 Trial
Josep-Maria Ribera et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation
Nicola Goekbuget et al.
BLOOD (2012)
Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies
Nicola Goekbuget et al.
BLOOD (2012)
Relapsing Hematologic Malignancies after Haploidentical Hematopoietic Stem Cell Transplantation
Yong-Xian Hu et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2011)
Modern Therapy of Acute Lymphoblastic Leukemia
Renato Bassan et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)
Renato Bassan et al.
BLOOD (2009)
Reduced-intensity allogeneic transplantation combined with imatinib mesylate for chronic myeloid leukemia in first chronic phase
Y. Luo et al.
LEUKEMIA (2009)
Share Paper
